Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Left versus right sided GI tumour response in the CRYSTAL trial

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 2014

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium

Prof Van Cutsem meets with ecancertv at ESMO 2016 to discuss the different treatment profiles of left or right sided colon cancers, as determined through the CRYSTAL study.

He describes how, depending on the tumour locations in reference to the splenic fracture, left sided tumours  responded more to the cetuximab FOLFIRI being administered in the trial, and considers how sidedness as a substitute for biomarkers is only a starting point for prognosis. 

Dr Van Cutsem reflects on other presentations from the conference, how they will guide clinical development and may result in improvements of care.

He also spoke with ecancer about the outcomes of the LUME study of nintedanib for colon cancer here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation